COVID-19 will have a heterogeneous impact on clinical trials, biopharmas

COVID-19 will have a heterogeneous impact on clinical trials, biopharmas

The novel coronavirus pandemic has created an unprecedented global health crisis. In response to the pandemic, dozens of countries and regions have instituted shelter-in-place orders and some institutions have issued guidelines urging people to minimize non-essential healthcare and/or clinical research. 

Impaired access to the healthcare system, travel restrictions, guidance from regulatory agencies, and a shift in resources to fighting the pandemic are beginning to impact the conduct of clinical trials. Angela De Martini, Leandra Plappert, Elizabeth Rountree, and Dean Lockhead held discussions with a selection of CRO, policy, regulatory, and venture capital experts to understand the implications of the pandemic on trials. The authors found that the pandemic will have an immediate (or short-term) impact on the conduct of trials, as well as a long-term impact that may reverberate through the industry in the coming years. 

To read the article published in Applied Clinical Trials, click here.